HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research Feb 24, 2022
HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market Feb 10, 2022
HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches May 17, 2021